Key facts
- OncoNano Medicine’s last known valuation is $60.0M (Jun 2025).
- It has raised $116.5M across 3 recorded rounds; the latest was Early Stage VC ($12.7M) in Apr 2025.
- Notable investors include National Institutes of Health, AG Collective Capital, Advantech Capital Partners, CKG Management, Cancer Prevention and Research Institute of Texas — 9 tracked in total.
- OncoNano Medicine has filed 7 Form Ds with the SEC since 2018, most recently Jun 2025 ($12.7M sold to 25 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for OncoNano Medicine
Funding rounds
3 roundsAbout OncoNano Medicine
Developer of a nanotechnology platform designed to improve the delivery and activation of cancer therapies in acidic tumor environments. The company offers an ultra pH-sensitive polymeric micelle system, which remains inactive in the bloodstream, helping surgeons to treat advanced cancer patients to access safer and more effective treatment options with reduced side effects.
- Sector
- Healthcare
- HQ
- Dallas, TX, United States
- Founded
- 2014
- Employees
- 23
- Website
- onconano.com/
- Ownership
- Privately Held (backing)
OncoNano Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoNano Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoNano Medicine in its N-PORT filings yet. We sweep new filings monthly.